IPO Timeline
Broker Results (T-2)
2021-12-21
Some brokers release in afternoon
Grey Market (T-1)
2021-12-22
Afternoon
HKEX Allotment (T-1)
2021-12-22
Evening
Registrar Allotment (T-1)
2021-12-22
Evening
Listing Day (T)
2021-12-23
First day of trading
Company Overview
| Stock Name | 上海百心安生物技術股份有限公司 - B - H股 |
|---|---|
| Stock Code | 02185 |
| Company Full Name | 上海百心安生物技術股份有限公司 - B - H股 |
| Industry | 醫療保健 |
| Principal Activities | 主要從事介入式心血管裝置業務，專注於研發全降解支架產品及腎神經阻斷系統。 |
| Listing Date | 2021-12-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國上海市浦東新區張江高科技產業東區瑞慶路590號4幢3層302室 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.bio-heart.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 21.25 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 50,872,500 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 20.1 |
|---|---|
| First Day Open | HK$ 18.88 |
| First Day Change | -5.41% |
| First Day Volume | 3952000.0 |
| First Day Turnover | 77091800.0 |
Use of Proceeds
| Use of Proceeds | 1、62.0%，或273.9百萬港元用于撥付正在進行的確認性臨床試驗、注冊備案的籌備事宜以及我們的核心產品Bioheart?的計劃中商業化上市； 2、21.3%，或94.1百萬港元用于撥付在中國正在進行的隨機對照臨床試驗以及我們的腎神經阻斷在研產品第二代Iberis?的持續開發； 3、6.7%，或29.6百萬港元用于撥付我們管線中其他在研產品的研發、進行中臨床前研究及已規劃的臨床試驗； 4、10.0%，或44.2百萬港元作一般企業及營運資金用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
华泰金融控股（香港）有限公司 CE AOK809
Overall Coordinators (1)
华泰金融控股（香港）有限公司 CE AOK809
Joint Bookrunners (1)
华泰金融控股（香港）有限公司 CE AOK809
Joint Lead Managers (1)
华泰金融控股（香港）有限公司 CE AOK809
Cornerstone Investors
This stock has no cornerstone investors.
Directors & Management
| Chairman | 汪立 |
|---|---|
| Company Secretary | 王云磬;郭兆瑩 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | Wang Li Philip & ASSO(43.75%);TPG Asia VII SF Pte. Ltd.(8.51%);Yang Xu & ASSO(6.85%) |
|---|
IPO Timeline
